Filing Details
Replimune Group, Inc. (NASDAQ:REPL) filed its annual report (Form 10-K) with the Securities and Exchange Commission on June 29, 2026.
The Healthcare company's annual report covers fiscal year 2026.
10k filedNASDAQ:REPL
Replimune Group, Inc. (REPL) Files Annual Report with SEC
Filing Details Replimune Group, Inc. (NASDAQ:REPL) filed its annual report (Form 10-K) with the Securities and Exchange Commission on June 29, 2026. The Healthcare company's…
Market Context
Replimune Group, Inc.'s stock currently trades at $11.20 with a market capitalization of $774.6M.
The 10-K is the most comprehensive annual report a public company files, containing detailed financial statements, management discussion and analysis (MD&A), risk factors, and business segment breakdowns. For Replimune Group, Inc. investors, the 10-K provides depth that quarterly reports don't — including full-year trends, long-term debt schedules, and off-balance-sheet items.
Key sections to review: MD&A for management's narrative on performance, risk factors for newly disclosed threats, and the notes to financial statements for accounting changes that could affect reported earnings.
All SEC filings for Replimune Group, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View REPL Stock Page
Frequently Asked Questions
Where can I read REPL's SEC filings?
Browse all filings on our REPL SEC filings page.
What types of SEC filings does Replimune Group, Inc. file?
Public companies like Replimune Group, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.